Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5luc1 is a replication-deficient adenoviral vector based on the human adenovirus serotype 5 (Ad5) platform. It is characterized by a deletion in the E1 region of the viral genome, which prevents it from replicating in non-complementing cell lines, and the inclusion of a luciferase reporter gene, typically driven by a Cytomegalovirus (CMV) promoter. In oncology and gene therapy research, Ad5luc1 is primarily utilized as a negative control for oncolytic (replication-competent) adenoviruses. It allows researchers to distinguish between biological effects resulting from initial viral transduction and transgene expression versus those caused by active viral replication and subsequent oncolysis. The vector utilizes the Coxsackievirus and Adenovirus Receptor (CAR) for cellular entry via its wild-type fiber protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ad5luc1.